<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cytori Therapeutics Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/cytori-therapeutics-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NBIX) Focus Turns To Biotech Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740</link>
		<comments>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740#comments</comments>
		<pubDate>Tue, 11 Jan 2011 23:46:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DATA]]></category>
		<category><![CDATA[DATATRAK International Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[GTF]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[Neurocrine Biosciences Inc]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64740</guid>
		<description><![CDATA[Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology  industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel. The event is attended by the “Who’s Who” of the healthcare industry, with currently over 350 companies registered to attend. Two smaller conferences will also take place next week concurrent with the massive J.P. Morgan conference, the 4th annual OneMed Forum 2011 held at the Sir Francis Drake Hotel and the Biotech Showcase 2011 held at the Parc 55 Wyndham Hotel feature smaller companies from the biotech and medical device industries. These conferences are an outstanding opportunity for biotech investors to meet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYTX) U.S. Government Stem Cell Policy Confusion Creates Opportunity</title>
		<link>http://www.stockbloghub.com/2010/08/25/cytx-u-s-government-stem-cell-policy-confusion-creates-opportunity/49261</link>
		<comments>http://www.stockbloghub.com/2010/08/25/cytx-u-s-government-stem-cell-policy-confusion-creates-opportunity/49261#comments</comments>
		<pubDate>Wed, 25 Aug 2010 17:06:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[CLI]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DCM]]></category>
		<category><![CDATA[Mack-Cali Realty Corporation]]></category>
		<category><![CDATA[NTT DoCoMo]]></category>
		<category><![CDATA[STEM]]></category>
		<category><![CDATA[StemCells Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49261</guid>
		<description><![CDATA[On Monday, August 23, 2010, the Federal District Court for the District of Columbia issued a temporary injunction on President Obama’s 2009 executive order that expanded federal funding for embryonic stem cell research, returning to order the previous ban enforced by the Bush administration in 2001. The news immediately halts National Institutes of Health (NIH) funding at academic and private research labs on embryonic stem cells. The ruling was a surprise, as several research programs had already initiated work under President Obama’s executive order. Controversy surrounding research using embryonic stem cells has grown since the NIH studies concluded in August 2000 that “&#8230;research involving human pluripotent stem cells&#8230;promises new treatments and possible cures for many debilitating diseases and injuries Incorporatedluding Parkinson&#8217;s disease, diabetes, heart disease, multiple sclerosis, burns and spinal cord injuries.”  ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/25/cytx-u-s-government-stem-cell-policy-confusion-creates-opportunity/49261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASTM) Aastrom Biosciences Analyst Initiates Coverage at Neutral</title>
		<link>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258</link>
		<comments>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258#comments</comments>
		<pubDate>Fri, 30 Jul 2010 14:32:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[CLI]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[NTT DoCoMo]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45258</guid>
		<description><![CDATA[We are initiating coverage of Aastrom Biosciences (ASTM) with a Neutral rating and $2.50 price target. Aastrom is pioneering the research effort on adult stem cells for therapeutic applications, specifically for the treatment of cardiovascular diseases such as critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom’s approach involves expansion of a patient’s own stem and progenitor cells outside of the body to generate a cell product with significantly increased numbers of highly functional early-stage cells. These autologous cell products can then be used for the repair or regeneration of multiple human tissues. The company has developed a proprietary Tissue Repair Cell technology in which cells are derived from a small amount of bone marrow taken from a patient and expanded in culture to generate a unique cell mixture containing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYTX) Cytori Therapeutics &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/07/15/cytx-cytori-therapeutics-bull-of-the-day-2/43502</link>
		<comments>http://www.stockbloghub.com/2010/07/15/cytx-cytori-therapeutics-bull-of-the-day-2/43502#comments</comments>
		<pubDate>Thu, 15 Jul 2010 15:22:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43502</guid>
		<description><![CDATA[We continue to be very positive on Cytori Therapeutics (CYTX) and believe the company&#8217;s Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years. Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results. Today&#8217;s price represents an attractive entry point. We are maintaining our Outperform rating and $10 target. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/15/cytx-cytori-therapeutics-bull-of-the-day-2/43502/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TWC) Adding Time Warner Cable to Wall Street Survivor Portfolio</title>
		<link>http://www.stockbloghub.com/2010/04/05/twc-adding-time-warner-cable-to-wall-street-survivor-portfolio/32711</link>
		<comments>http://www.stockbloghub.com/2010/04/05/twc-adding-time-warner-cable-to-wall-street-survivor-portfolio/32711#comments</comments>
		<pubDate>Mon, 05 Apr 2010 17:46:28 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Regional Airlines]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[GOL]]></category>
		<category><![CDATA[GOL Linhas Aéreas Inteligentes S.A.]]></category>
		<category><![CDATA[Time Warner Cable Inc.]]></category>
		<category><![CDATA[TWC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32711</guid>
		<description><![CDATA[In my Wall Street Survivor portfolio I had to clear some deadwood. GOL Linhaus Aereas Inteligentes SA ( GOL ) and Cytori Therapeutics ( CYTX ) just quit performing the way I wanted them to. Both have dropped below their 20, 50 and even 100 day moving averages, so they have no place in my momentum based portfolio. I wanted a large more stable company for my portfolio so I used Barchart to screen the S&#38;P 500 stocks having the highest relative strength and Time Warner Cable ( TWC ) was near the top of the list. It has been a long time since I looked at cable TV companies and thought of them as just a simple utility company where you take the number of subscribers times the monthly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/twc-adding-time-warner-cable-to-wall-street-survivor-portfolio/32711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GOL) Time Warner Cable Added to Wall Street Survivor Portfolio</title>
		<link>http://www.stockbloghub.com/2010/04/01/gol-time-warner-cable-added-to-wall-street-survivor-portfolio/32532</link>
		<comments>http://www.stockbloghub.com/2010/04/01/gol-time-warner-cable-added-to-wall-street-survivor-portfolio/32532#comments</comments>
		<pubDate>Thu, 01 Apr 2010 14:58:21 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Regional Airlines]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[GOL]]></category>
		<category><![CDATA[GOL Linhas Aéreas Inteligentes S.A.]]></category>
		<category><![CDATA[Time Warner Cable Inc.]]></category>
		<category><![CDATA[TWC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32532</guid>
		<description><![CDATA[In my Wall Street Survivor portfolio I had to clear some deadwood. GOL Linhaus Aereas Inteligentes SA ( GOL ) and Cytori Therapeutics ( CYTX ) just quit performing the way I wanted them to. Both have dropped below their 20, 50 and even 100 day moving averages, so they have no place in my momentum based portfolio. I wanted a large more stable company for my portfolio so I used Barchart to screen the S&#38;P 500 stocks having the highest relative strength and Time Warner Cable ( TWC ) was near the top of the list. It has been a long time since I looked at cable TV companies and thought of them as just a simple utility company where you take the number of subscribers times the monthly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/gol-time-warner-cable-added-to-wall-street-survivor-portfolio/32532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYTX) Cytori Therapeutics Plans Meeting With FDA on Clinical Program for Celution System</title>
		<link>http://www.stockbloghub.com/2010/03/18/cytx-cytori-therapeutics-plans-meeting-with-fda-on-clinical-program-for-celution-system/30713</link>
		<comments>http://www.stockbloghub.com/2010/03/18/cytx-cytori-therapeutics-plans-meeting-with-fda-on-clinical-program-for-celution-system/30713#comments</comments>
		<pubDate>Thu, 18 Mar 2010 21:17:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30713</guid>
		<description><![CDATA[Last week, Cytori Therapeutics (CYTX) was notified by the U.S. FDA that they will be required to conduct a clinical program prior to final approval of its Celution System. This was in-line with our expectations. Management plans to meet with the FDA in the next few months to discuss the requirements necessary for the Pre-Market Approval (PMA) program. Assuming the meeting takes place this second quarter, Cytori should be in position to file the investigation device exemption (IDE) and initiate the program by the end of the year. Our best guess is that the FDA will require Cytori to conduct a 12-month study in approximately 100 patients looking at endpoints similar to the RESTORE-2 program conducted in Europe Incorporatedluding graft retention, patient and physician satisfaction and safety. If all goes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/cytx-cytori-therapeutics-plans-meeting-with-fda-on-clinical-program-for-celution-system/30713/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYTX) Cytori Therapeutics &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/10/19/cytx-cytori-therapeutics-bull-of-the-day/18089</link>
		<comments>http://www.stockbloghub.com/2009/10/19/cytx-cytori-therapeutics-bull-of-the-day/18089#comments</comments>
		<pubDate>Mon, 19 Oct 2009 16:38:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18089</guid>
		<description><![CDATA[We continue to be very positive on Cytori Therapeutics (CYTX) and believe the company&#8217;s Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years. Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results. Today&#8217;s price represents a very attractive entry point in our view. We are maintaining our Outperform rating and $8 target. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/19/cytx-cytori-therapeutics-bull-of-the-day/18089/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

